Вестник Ассоциации пульмонологов Центральной Азии Volume 13 Issue 8 (2025) · pp. 21-26
COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY
Mullokulov J.J., Akhmedov Kh.S.
Abstract
Reactive arthritis (ReA) is a post-infectious spondyloarthritis characterized by arthritis, enthesitis, and extra-articular features. Conventional treatments such as sulfasalazine (SSZ) show modest benefit, while TNF-α inhibitors are effective but limited by cost and accessibility. Baricitinib, a JAK1/2 inhibitor, offers a novel oral therapeutic strategy, though evidence in ReA is scarce.
reactive arthritis, baricitinib, adalimumab, DAREA, BASDAI.
Metadata source: the journal's OAI-PMH archive · Sindex does not store the full text; it links to the source.